Marco Del Chiaro
Concepts (599)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 183 | 2026 | 944 | 33.720 |
Why?
| | Pancreatectomy | 84 | 2026 | 289 | 19.760 |
Why?
| | Carcinoma, Pancreatic Ductal | 72 | 2026 | 297 | 17.510 |
Why?
| | Pancreaticoduodenectomy | 36 | 2026 | 149 | 6.960 |
Why?
| | Adenocarcinoma | 33 | 2026 | 927 | 6.870 |
Why?
| | Neoadjuvant Therapy | 33 | 2026 | 475 | 6.760 |
Why?
| | Adenocarcinoma, Mucinous | 18 | 2025 | 76 | 5.190 |
Why?
| | Mesenteric Veins | 11 | 2025 | 28 | 4.930 |
Why?
| | Portal Vein | 16 | 2026 | 123 | 4.200 |
Why?
| | Pancreas | 41 | 2026 | 343 | 4.160 |
Why?
| | Carcinoma, Papillary | 11 | 2025 | 83 | 2.930 |
Why?
| | Pancreatic Cyst | 12 | 2025 | 50 | 2.770 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 19 | 2026 | 1998 | 2.560 |
Why?
| | Ampulla of Vater | 8 | 2026 | 40 | 2.190 |
Why?
| | Common Bile Duct Neoplasms | 7 | 2026 | 28 | 2.160 |
Why?
| | Pancreatic Fistula | 11 | 2023 | 35 | 2.080 |
Why?
| | Retrospective Studies | 101 | 2026 | 17438 | 2.040 |
Why?
| | Postoperative Complications | 35 | 2026 | 3034 | 1.930 |
Why?
| | Aged | 102 | 2026 | 26432 | 1.930 |
Why?
| | Humans | 262 | 2026 | 146342 | 1.880 |
Why?
| | CA-19-9 Antigen | 5 | 2026 | 36 | 1.850 |
Why?
| | Survival Rate | 26 | 2026 | 2092 | 1.770 |
Why?
| | Pancreatic Ducts | 10 | 2022 | 81 | 1.720 |
Why?
| | Middle Aged | 110 | 2026 | 36619 | 1.650 |
Why?
| | Prognosis | 33 | 2026 | 4351 | 1.620 |
Why?
| | Vascular Surgical Procedures | 6 | 2025 | 352 | 1.550 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2026 | 1160 | 1.520 |
Why?
| | Exocrine Pancreatic Insufficiency | 5 | 2019 | 25 | 1.500 |
Why?
| | Mesenteric Artery, Superior | 5 | 2026 | 28 | 1.450 |
Why?
| | Chemotherapy, Adjuvant | 17 | 2026 | 429 | 1.430 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 74 | 1.320 |
Why?
| | Male | 126 | 2026 | 73396 | 1.310 |
Why?
| | Aged, 80 and over | 46 | 2025 | 8391 | 1.300 |
Why?
| | Early Detection of Cancer | 6 | 2021 | 506 | 1.300 |
Why?
| | Pancreas Transplantation | 24 | 2010 | 70 | 1.230 |
Why?
| | Female | 123 | 2026 | 79499 | 1.210 |
Why?
| | Treatment Outcome | 44 | 2026 | 11821 | 1.100 |
Why?
| | Pancreatitis, Chronic | 6 | 2020 | 64 | 1.070 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 4 | 2025 | 27 | 1.020 |
Why?
| | Neoplasm Staging | 15 | 2025 | 1488 | 1.000 |
Why?
| | Databases, Factual | 4 | 2025 | 1493 | 0.990 |
Why?
| | Adult | 77 | 2026 | 41087 | 0.940 |
Why?
| | Quality of Life | 8 | 2025 | 3200 | 0.940 |
Why?
| | Anastomotic Leak | 2 | 2025 | 46 | 0.930 |
Why?
| | Neoplasm Invasiveness | 10 | 2026 | 504 | 0.920 |
Why?
| | Chyle | 1 | 2025 | 4 | 0.920 |
Why?
| | Islets of Langerhans | 5 | 2020 | 852 | 0.920 |
Why?
| | Carcinoma, Neuroendocrine | 2 | 2023 | 38 | 0.910 |
Why?
| | Follow-Up Studies | 24 | 2025 | 5439 | 0.910 |
Why?
| | Venous Thrombosis | 2 | 2025 | 199 | 0.910 |
Why?
| | Endosonography | 5 | 2021 | 160 | 0.900 |
Why?
| | Frozen Sections | 1 | 2025 | 23 | 0.870 |
Why?
| | Cystadenocarcinoma, Mucinous | 3 | 2026 | 12 | 0.870 |
Why?
| | Biomarkers, Tumor | 14 | 2026 | 1339 | 0.870 |
Why?
| | Precancerous Conditions | 3 | 2015 | 162 | 0.850 |
Why?
| | Nomograms | 3 | 2022 | 59 | 0.850 |
Why?
| | Liver Neoplasms | 4 | 2024 | 776 | 0.830 |
Why?
| | Hepatoblastoma | 1 | 2024 | 52 | 0.800 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 26 | 0.790 |
Why?
| | Thrombelastography | 2 | 2024 | 182 | 0.780 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2020 | 196 | 0.710 |
Why?
| | Fluorouracil | 11 | 2025 | 231 | 0.700 |
Why?
| | Leucovorin | 8 | 2025 | 98 | 0.670 |
Why?
| | Surgical Stapling | 1 | 2021 | 14 | 0.660 |
Why?
| | Absorbable Implants | 1 | 2021 | 38 | 0.650 |
Why?
| | Risk Assessment | 11 | 2025 | 3712 | 0.650 |
Why?
| | Incidence | 11 | 2026 | 2936 | 0.650 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 228 | 0.650 |
Why?
| | Organ Transplantation | 2 | 2023 | 244 | 0.630 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 103 | 0.630 |
Why?
| | Sweden | 6 | 2025 | 114 | 0.620 |
Why?
| | Liver Transplantation | 4 | 2024 | 751 | 0.610 |
Why?
| | Neoplasms, Multiple Primary | 3 | 2015 | 57 | 0.610 |
Why?
| | Vascular Neoplasms | 1 | 2020 | 19 | 0.610 |
Why?
| | Arteries | 2 | 2019 | 261 | 0.610 |
Why?
| | Risk Factors | 21 | 2026 | 10921 | 0.610 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2017 | 11 | 0.590 |
Why?
| | Deoxycytidine | 9 | 2025 | 219 | 0.590 |
Why?
| | Pancreatitis | 5 | 2022 | 146 | 0.590 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 35 | 0.590 |
Why?
| | Practice Guidelines as Topic | 4 | 2026 | 1591 | 0.580 |
Why?
| | Neuroendocrine Tumors | 4 | 2023 | 122 | 0.550 |
Why?
| | Neoplasm Metastasis | 2 | 2025 | 693 | 0.530 |
Why?
| | Cohort Studies | 12 | 2024 | 6077 | 0.520 |
Why?
| | Evidence-Based Medicine | 5 | 2024 | 731 | 0.520 |
Why?
| | Living Donors | 3 | 2016 | 216 | 0.510 |
Why?
| | Europe | 8 | 2021 | 421 | 0.500 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.500 |
Why?
| | Metabolomics | 2 | 2019 | 738 | 0.490 |
Why?
| | Kidney Transplantation | 17 | 2016 | 735 | 0.480 |
Why?
| | Prospective Studies | 17 | 2026 | 8123 | 0.480 |
Why?
| | Hepatic Artery | 4 | 2020 | 53 | 0.480 |
Why?
| | Patient Selection | 9 | 2024 | 728 | 0.480 |
Why?
| | Celiac Artery | 4 | 2020 | 19 | 0.470 |
Why?
| | Hepatitis B virus | 1 | 2016 | 33 | 0.470 |
Why?
| | Pancreaticojejunostomy | 3 | 2022 | 8 | 0.460 |
Why?
| | Watchful Waiting | 1 | 2016 | 90 | 0.460 |
Why?
| | Disease Progression | 6 | 2025 | 2867 | 0.450 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 96 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1408 | 0.430 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 37 | 0.430 |
Why?
| | Pancreatic Diseases | 3 | 2020 | 64 | 0.430 |
Why?
| | Survival Analysis | 12 | 2024 | 1378 | 0.420 |
Why?
| | Adenoma | 3 | 2025 | 210 | 0.420 |
Why?
| | Laparoscopy | 4 | 2025 | 487 | 0.410 |
Why?
| | Postoperative Care | 3 | 2026 | 301 | 0.410 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 2219 | 0.390 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2024 | 222 | 0.390 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 4 | 2019 | 218 | 0.390 |
Why?
| | Japan | 5 | 2025 | 149 | 0.380 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1064 | 0.380 |
Why?
| | Cystadenocarcinoma | 1 | 2013 | 4 | 0.380 |
Why?
| | Cystadenoma | 1 | 2013 | 5 | 0.380 |
Why?
| | Combined Modality Therapy | 5 | 2024 | 1271 | 0.380 |
Why?
| | Robotics | 1 | 2014 | 89 | 0.380 |
Why?
| | Propensity Score | 4 | 2026 | 376 | 0.370 |
Why?
| | Italy | 11 | 2013 | 118 | 0.360 |
Why?
| | Cystadenoma, Serous | 3 | 2020 | 18 | 0.360 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 370 | 0.360 |
Why?
| | Stomach Neoplasms | 2 | 2024 | 128 | 0.360 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 467 | 0.350 |
Why?
| | Diabetes Mellitus | 3 | 2019 | 1101 | 0.350 |
Why?
| | Tomography, X-Ray Computed | 10 | 2021 | 2786 | 0.350 |
Why?
| | Diagnosis, Differential | 8 | 2022 | 1503 | 0.350 |
Why?
| | Dilatation, Pathologic | 3 | 2020 | 60 | 0.340 |
Why?
| | Peritoneal Neoplasms | 2 | 2024 | 103 | 0.340 |
Why?
| | Lymphatic Metastasis | 4 | 2026 | 335 | 0.340 |
Why?
| | Palliative Care | 3 | 2019 | 1032 | 0.340 |
Why?
| | Benchmarking | 3 | 2026 | 193 | 0.330 |
Why?
| | Cystadenoma, Mucinous | 2 | 2026 | 11 | 0.330 |
Why?
| | Predictive Value of Tests | 7 | 2025 | 2113 | 0.330 |
Why?
| | Risk | 5 | 2022 | 920 | 0.320 |
Why?
| | Gastroenterology | 2 | 2023 | 187 | 0.320 |
Why?
| | Gamma Rays | 2 | 2021 | 56 | 0.320 |
Why?
| | Adolescent | 17 | 2026 | 22557 | 0.320 |
Why?
| | Age Factors | 7 | 2025 | 3347 | 0.310 |
Why?
| | Microbiota | 3 | 2025 | 725 | 0.310 |
Why?
| | Portal System | 6 | 2020 | 12 | 0.310 |
Why?
| | Chemoradiotherapy | 2 | 2022 | 238 | 0.300 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2010 | 47 | 0.300 |
Why?
| | Young Adult | 13 | 2026 | 14330 | 0.300 |
Why?
| | Neoplasm Grading | 4 | 2020 | 313 | 0.300 |
Why?
| | Time Factors | 11 | 2024 | 7109 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3926 | 0.300 |
Why?
| | Tissue Donors | 14 | 2005 | 425 | 0.290 |
Why?
| | Decision Making | 1 | 2016 | 993 | 0.280 |
Why?
| | Kidney | 2 | 2016 | 1498 | 0.280 |
Why?
| | Population Surveillance | 2 | 2019 | 481 | 0.270 |
Why?
| | Tumor Burden | 2 | 2022 | 326 | 0.270 |
Why?
| | Mass Screening | 2 | 2019 | 1307 | 0.260 |
Why?
| | Software | 2 | 2017 | 676 | 0.260 |
Why?
| | Graft Survival | 12 | 2005 | 523 | 0.260 |
Why?
| | Margins of Excision | 2 | 2025 | 55 | 0.250 |
Why?
| | Internationality | 4 | 2020 | 156 | 0.250 |
Why?
| | Islets of Langerhans Transplantation | 3 | 2020 | 72 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2488 | 0.240 |
Why?
| | Family Health | 1 | 2007 | 194 | 0.240 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2024 | 69 | 0.240 |
Why?
| | Disease-Free Survival | 5 | 2023 | 778 | 0.240 |
Why?
| | Drainage | 10 | 2022 | 187 | 0.240 |
Why?
| | Pedigree | 3 | 2014 | 512 | 0.240 |
Why?
| | Intention to Treat Analysis | 1 | 2026 | 78 | 0.230 |
Why?
| | Multidetector Computed Tomography | 2 | 2016 | 40 | 0.230 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 156 | 0.230 |
Why?
| | Prevalence | 4 | 2025 | 2861 | 0.230 |
Why?
| | Observer Variation | 2 | 2024 | 356 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1712 | 0.230 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2026 | 64 | 0.220 |
Why?
| | Cyst Fluid | 2 | 2022 | 20 | 0.220 |
Why?
| | Pilot Projects | 6 | 2026 | 1888 | 0.220 |
Why?
| | Netherlands | 4 | 2026 | 85 | 0.220 |
Why?
| | Length of Stay | 5 | 2021 | 1358 | 0.220 |
Why?
| | Diarrhea | 1 | 2026 | 190 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2026 | 106 | 0.220 |
Why?
| | Symptom Assessment | 1 | 2026 | 138 | 0.220 |
Why?
| | Cholangiocarcinoma | 2 | 2024 | 110 | 0.220 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 39 | 0.210 |
Why?
| | Pylorus | 1 | 2024 | 17 | 0.210 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2019 | 44 | 0.210 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1331 | 0.210 |
Why?
| | Gallbladder Neoplasms | 1 | 2024 | 20 | 0.210 |
Why?
| | Spheroids, Cellular | 1 | 2025 | 81 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2026 | 314 | 0.200 |
Why?
| | Perioperative Care | 2 | 2024 | 235 | 0.200 |
Why?
| | Lymph Node Excision | 1 | 2024 | 174 | 0.190 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.190 |
Why?
| | Incidental Findings | 2 | 2021 | 81 | 0.190 |
Why?
| | Hyperemia | 1 | 2023 | 49 | 0.190 |
Why?
| | Child, Preschool | 6 | 2026 | 11913 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2024 | 132 | 0.180 |
Why?
| | Hospital Mortality | 4 | 2020 | 1051 | 0.180 |
Why?
| | Surgical Oncology | 1 | 2022 | 30 | 0.180 |
Why?
| | Hyperamylasemia | 1 | 2022 | 3 | 0.180 |
Why?
| | Sensitivity and Specificity | 3 | 2026 | 1998 | 0.180 |
Why?
| | Reoperation | 7 | 2018 | 645 | 0.180 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 214 | 0.180 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2022 | 14 | 0.180 |
Why?
| | Forecasting | 1 | 2023 | 388 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 259 | 0.170 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2021 | 4 | 0.170 |
Why?
| | Bacteria | 2 | 2025 | 766 | 0.170 |
Why?
| | Plastics | 1 | 2022 | 50 | 0.170 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2021 | 26 | 0.170 |
Why?
| | Pathology, Clinical | 1 | 2021 | 29 | 0.170 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2022 | 115 | 0.170 |
Why?
| | Datasets as Topic | 1 | 2021 | 120 | 0.170 |
Why?
| | Cysts | 1 | 2022 | 108 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 417 | 0.160 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.160 |
Why?
| | Surgical Mesh | 1 | 2021 | 54 | 0.160 |
Why?
| | Fusobacterium nucleatum | 1 | 2020 | 4 | 0.160 |
Why?
| | Fusobacterium Infections | 1 | 2020 | 7 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.160 |
Why?
| | Body Composition | 1 | 2024 | 689 | 0.160 |
Why?
| | United States | 5 | 2025 | 16136 | 0.160 |
Why?
| | Albumins | 3 | 2025 | 120 | 0.160 |
Why?
| | Surgeons | 1 | 2025 | 351 | 0.160 |
Why?
| | Microdissection | 2 | 2011 | 13 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 115 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 122 | 0.150 |
Why?
| | Blood | 1 | 2020 | 107 | 0.150 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2010 | 108 | 0.150 |
Why?
| | Quality Improvement | 2 | 2026 | 1354 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 147 | 0.150 |
Why?
| | Cyclosporine | 4 | 2005 | 256 | 0.150 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 78 | 0.150 |
Why?
| | Comorbidity | 2 | 2022 | 1665 | 0.150 |
Why?
| | Paclitaxel | 3 | 2025 | 260 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Conservative Treatment | 1 | 2020 | 45 | 0.150 |
Why?
| | Lasers | 2 | 2011 | 127 | 0.150 |
Why?
| | Dilatation | 1 | 2019 | 73 | 0.150 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 90 | 0.140 |
Why?
| | Biliary Tract Diseases | 1 | 2019 | 32 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 219 | 0.140 |
Why?
| | Bacterial Infections | 1 | 2021 | 247 | 0.140 |
Why?
| | Laparotomy | 2 | 2016 | 111 | 0.140 |
Why?
| | Bile Ducts | 1 | 2019 | 66 | 0.140 |
Why?
| | Immunosuppressive Agents | 6 | 2005 | 829 | 0.140 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 150 | 0.140 |
Why?
| | Mouth | 1 | 2019 | 84 | 0.140 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 216 | 0.140 |
Why?
| | Saliva | 1 | 2020 | 256 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1432 | 0.140 |
Why?
| | Nutritional Support | 1 | 2018 | 39 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 568 | 0.140 |
Why?
| | Iopamidol | 2 | 2016 | 12 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 4 | 2005 | 663 | 0.130 |
Why?
| | DNA Damage | 1 | 2021 | 439 | 0.130 |
Why?
| | Jejunum | 2 | 2016 | 36 | 0.130 |
Why?
| | Patient Care Team | 3 | 2020 | 701 | 0.130 |
Why?
| | Carcinoma | 1 | 2019 | 225 | 0.130 |
Why?
| | Insulin | 8 | 2013 | 2525 | 0.130 |
Why?
| | Societies, Medical | 2 | 2020 | 907 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2019 | 319 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2024 | 881 | 0.130 |
Why?
| | Preoperative Care | 2 | 2026 | 396 | 0.130 |
Why?
| | Logistic Models | 2 | 2020 | 2126 | 0.130 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 6073 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 970 | 0.130 |
Why?
| | Malnutrition | 1 | 2018 | 87 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 881 | 0.130 |
Why?
| | Radiosurgery | 1 | 2020 | 398 | 0.120 |
Why?
| | Hepatic Duct, Common | 1 | 2016 | 5 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1221 | 0.120 |
Why?
| | Jaundice, Obstructive | 1 | 2016 | 3 | 0.120 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5899 | 0.120 |
Why?
| | Epitopes | 1 | 2018 | 479 | 0.120 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2016 | 24 | 0.120 |
Why?
| | Triiodobenzoic Acids | 1 | 2016 | 6 | 0.120 |
Why?
| | Organ Preservation Solutions | 3 | 2005 | 47 | 0.120 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 56 | 0.120 |
Why?
| | Hyperglycemia | 1 | 2020 | 384 | 0.120 |
Why?
| | Radiographic Image Enhancement | 1 | 2016 | 57 | 0.110 |
Why?
| | Sex Factors | 1 | 2022 | 2107 | 0.110 |
Why?
| | Cannabis | 1 | 2023 | 521 | 0.110 |
Why?
| | Bacteriocins | 1 | 2015 | 5 | 0.110 |
Why?
| | Hepatitis B | 1 | 2016 | 66 | 0.110 |
Why?
| | Embolization, Therapeutic | 1 | 2018 | 246 | 0.110 |
Why?
| | Genes, BRCA2 | 1 | 2015 | 33 | 0.110 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 102 | 0.110 |
Why?
| | Genes, BRCA1 | 1 | 2015 | 45 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2018 | 781 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 725 | 0.110 |
Why?
| | Papilloma, Intraductal | 1 | 2014 | 1 | 0.110 |
Why?
| | Heredity | 1 | 2014 | 13 | 0.110 |
Why?
| | Organ Preservation | 3 | 2004 | 123 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 594 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 10 | 2010 | 3930 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2021 | 1130 | 0.100 |
Why?
| | Apoptosis | 6 | 2021 | 2439 | 0.100 |
Why?
| | Germany | 2 | 2024 | 139 | 0.100 |
Why?
| | Risk Adjustment | 1 | 2014 | 86 | 0.100 |
Why?
| | Genomics | 2 | 2017 | 853 | 0.100 |
Why?
| | Amylases | 1 | 2013 | 18 | 0.100 |
Why?
| | Neoplasm, Residual | 1 | 2014 | 143 | 0.100 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.100 |
Why?
| | Tissue and Organ Harvesting | 5 | 2005 | 69 | 0.100 |
Why?
| | MicroRNAs | 2 | 2010 | 699 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 219 | 0.100 |
Why?
| | Reproducibility of Results | 6 | 2019 | 3416 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2025 | 541 | 0.100 |
Why?
| | North America | 2 | 2024 | 300 | 0.100 |
Why?
| | Tacrolimus | 2 | 2005 | 192 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2921 | 0.100 |
Why?
| | Perception | 1 | 2016 | 373 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2021 | 2502 | 0.100 |
Why?
| | Antibodies, Monoclonal | 4 | 2005 | 1512 | 0.100 |
Why?
| | Syndrome | 1 | 2014 | 380 | 0.100 |
Why?
| | Abdomen | 2 | 2004 | 142 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 462 | 0.090 |
Why?
| | Cadaver | 8 | 2005 | 304 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 340 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2024 | 2418 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 582 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2014 | 178 | 0.090 |
Why?
| | Insulin-Secreting Cells | 2 | 2007 | 393 | 0.090 |
Why?
| | ROC Curve | 3 | 2024 | 617 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 677 | 0.090 |
Why?
| | Immunotherapy, Adoptive | 1 | 2016 | 356 | 0.090 |
Why?
| | Endoscopy | 1 | 2014 | 316 | 0.090 |
Why?
| | Child | 6 | 2026 | 22693 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2015 | 355 | 0.090 |
Why?
| | C-Reactive Protein | 1 | 2013 | 429 | 0.080 |
Why?
| | Neoplasms | 2 | 2022 | 2954 | 0.080 |
Why?
| | Loss of Heterozygosity | 1 | 2011 | 51 | 0.080 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 45 | 0.080 |
Why?
| | Graft Rejection | 5 | 2005 | 516 | 0.080 |
Why?
| | Biomarkers | 1 | 2022 | 4340 | 0.080 |
Why?
| | Raffinose | 3 | 2005 | 29 | 0.080 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 83 | 0.080 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 305 | 0.080 |
Why?
| | Disaccharides | 3 | 2005 | 21 | 0.080 |
Why?
| | Mannitol | 3 | 2005 | 42 | 0.080 |
Why?
| | Glucose | 3 | 2020 | 1053 | 0.080 |
Why?
| | Allopurinol | 3 | 2005 | 70 | 0.080 |
Why?
| | Histidine | 3 | 2005 | 67 | 0.080 |
Why?
| | Glutamates | 3 | 2005 | 66 | 0.080 |
Why?
| | Electrolytes | 3 | 2005 | 52 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2675 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2016 | 931 | 0.070 |
Why?
| | Duodenum | 1 | 2010 | 76 | 0.070 |
Why?
| | Lymph Nodes | 2 | 2024 | 511 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2014 | 702 | 0.070 |
Why?
| | Peptides | 1 | 2015 | 992 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 882 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3545 | 0.070 |
Why?
| | Down-Regulation | 1 | 2011 | 614 | 0.070 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 104 | 0.070 |
Why?
| | Adenosine | 3 | 2005 | 256 | 0.070 |
Why?
| | Glutathione | 3 | 2005 | 369 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 249 | 0.070 |
Why?
| | Enzyme Replacement Therapy | 2 | 2018 | 15 | 0.070 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 415 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2026 | 1135 | 0.070 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 180 | 0.060 |
Why?
| | Morbidity | 2 | 2019 | 319 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2010 | 636 | 0.060 |
Why?
| | Gliclazide | 1 | 2007 | 2 | 0.060 |
Why?
| | Consensus | 2 | 2020 | 467 | 0.060 |
Why?
| | Diabetic Retinopathy | 2 | 2006 | 211 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2018 | 224 | 0.060 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2006 | 19 | 0.060 |
Why?
| | Arterial Occlusive Diseases | 1 | 2007 | 88 | 0.060 |
Why?
| | Extracorporeal Circulation | 1 | 2006 | 15 | 0.060 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 365 | 0.060 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 117 | 0.060 |
Why?
| | Pancreatic Pseudocyst | 1 | 2025 | 18 | 0.060 |
Why?
| | Hepatic Veins | 1 | 2006 | 28 | 0.060 |
Why?
| | C-Peptide | 1 | 2007 | 191 | 0.060 |
Why?
| | Hepatectomy | 2 | 2024 | 256 | 0.060 |
Why?
| | Lacerations | 1 | 2006 | 38 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2007 | 287 | 0.060 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 80 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 747 | 0.050 |
Why?
| | Smartphone | 1 | 2026 | 103 | 0.050 |
Why?
| | Alcohol Drinking | 2 | 2013 | 850 | 0.050 |
Why?
| | Smoking | 2 | 2013 | 1486 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2006 | 306 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Abdominal Injuries | 1 | 2006 | 122 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 237 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 893 | 0.050 |
Why?
| | Bezoars | 1 | 2004 | 4 | 0.050 |
Why?
| | Jehovah's Witnesses | 1 | 2004 | 3 | 0.050 |
Why?
| | Succinimides | 1 | 2024 | 21 | 0.050 |
Why?
| | Biopsy | 3 | 2019 | 1075 | 0.050 |
Why?
| | Contrast Media | 3 | 2016 | 493 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 204 | 0.050 |
Why?
| | Splenectomy | 1 | 2024 | 61 | 0.050 |
Why?
| | Chemotaxis | 1 | 2004 | 121 | 0.050 |
Why?
| | Intestinal Obstruction | 1 | 2004 | 54 | 0.050 |
Why?
| | Cystectomy | 1 | 2003 | 46 | 0.050 |
Why?
| | Mobile Applications | 1 | 2026 | 196 | 0.050 |
Why?
| | RNA, Messenger | 5 | 2011 | 2791 | 0.050 |
Why?
| | Antioxidants | 1 | 2007 | 544 | 0.050 |
Why?
| | Intestine, Small | 1 | 2004 | 160 | 0.050 |
Why?
| | Postoperative Period | 2 | 2019 | 355 | 0.050 |
Why?
| | Ileum | 1 | 2003 | 112 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2004 | 157 | 0.050 |
Why?
| | Wounds, Nonpenetrating | 1 | 2006 | 305 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 561 | 0.040 |
Why?
| | Delphi Technique | 1 | 2024 | 350 | 0.040 |
Why?
| | Carbohydrates | 1 | 2022 | 66 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2026 | 706 | 0.040 |
Why?
| | Program Evaluation | 1 | 2026 | 952 | 0.040 |
Why?
| | Genetic Testing | 1 | 2005 | 492 | 0.040 |
Why?
| | Azathioprine | 1 | 2001 | 43 | 0.040 |
Why?
| | Stents | 2 | 2022 | 554 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2026 | 516 | 0.040 |
Why?
| | Gastrectomy | 1 | 2023 | 164 | 0.040 |
Why?
| | Creatinine | 4 | 2004 | 511 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2003 | 194 | 0.040 |
Why?
| | Vascular Diseases | 1 | 2004 | 252 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 974 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2025 | 594 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2001 | 117 | 0.040 |
Why?
| | Necrosis | 1 | 2022 | 243 | 0.040 |
Why?
| | Retroperitoneal Space | 3 | 2005 | 19 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Hernia, Inguinal | 1 | 2001 | 47 | 0.040 |
Why?
| | Steroids | 1 | 2001 | 160 | 0.040 |
Why?
| | Endometriosis | 1 | 2001 | 58 | 0.040 |
Why?
| | Hyperplasia | 1 | 2021 | 164 | 0.040 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2023 | 236 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 259 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 83 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2022 | 3647 | 0.040 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 92 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 642 | 0.040 |
Why?
| | Capecitabine | 1 | 2019 | 56 | 0.040 |
Why?
| | Secretin | 2 | 2010 | 6 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 38 | 0.040 |
Why?
| | Republic of Korea | 1 | 2019 | 43 | 0.040 |
Why?
| | Florida | 1 | 2020 | 117 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 345 | 0.040 |
Why?
| | Asia | 1 | 2019 | 69 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 6034 | 0.040 |
Why?
| | Treatment Failure | 3 | 2005 | 361 | 0.040 |
Why?
| | Mice | 3 | 2022 | 18297 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 193 | 0.040 |
Why?
| | Patient Discharge | 1 | 2026 | 997 | 0.040 |
Why?
| | Cell Death | 1 | 2021 | 379 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 704 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2016 | 4118 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 119 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 335 | 0.040 |
Why?
| | Aquaporin 1 | 1 | 2018 | 3 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 1038 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 668 | 0.040 |
Why?
| | Radiotherapy | 1 | 2019 | 209 | 0.040 |
Why?
| | Pancreatic Elastase | 1 | 2018 | 54 | 0.030 |
Why?
| | Stromal Cells | 1 | 2019 | 123 | 0.030 |
Why?
| | Cause of Death | 3 | 2005 | 456 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2020 | 226 | 0.030 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2010 | 23 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1543 | 0.030 |
Why?
| | Hospitals, High-Volume | 1 | 2018 | 51 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 930 | 0.030 |
Why?
| | Preoperative Period | 1 | 2018 | 157 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 530 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2010 | 752 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 352 | 0.030 |
Why?
| | Intestinal Neoplasms | 1 | 2016 | 31 | 0.030 |
Why?
| | Registries | 1 | 2025 | 2400 | 0.030 |
Why?
| | Diabetic Nephropathies | 3 | 2005 | 320 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 951 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 250 | 0.030 |
Why?
| | Drug Therapy, Combination | 3 | 2004 | 1036 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 729 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 192 | 0.030 |
Why?
| | Transplantation, Homologous | 2 | 2010 | 416 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 346 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 210 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 164 | 0.030 |
Why?
| | Vitamins | 1 | 2017 | 183 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 121 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2814 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1143 | 0.030 |
Why?
| | Feces | 1 | 2018 | 496 | 0.030 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2014 | 11 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1163 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2019 | 565 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 193 | 0.030 |
Why?
| | Animals | 3 | 2022 | 38107 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 68 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2016 | 271 | 0.030 |
Why?
| | Kidney Failure, Chronic | 3 | 2004 | 589 | 0.020 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 97 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2022 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2016 | 369 | 0.020 |
Why?
| | Indole Alkaloids | 1 | 2013 | 7 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2005 | 790 | 0.020 |
Why?
| | Cytokines | 2 | 2016 | 2081 | 0.020 |
Why?
| | Drug Interactions | 2 | 2005 | 405 | 0.020 |
Why?
| | Peptic Ulcer | 1 | 2013 | 18 | 0.020 |
Why?
| | Pregnancy | 1 | 2026 | 7230 | 0.020 |
Why?
| | Biomedical Research | 1 | 2019 | 729 | 0.020 |
Why?
| | Histocompatibility Testing | 2 | 2004 | 124 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1849 | 0.020 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 102 | 0.020 |
Why?
| | Safety | 2 | 2004 | 347 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2016 | 1137 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 403 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.020 |
Why?
| | Hypoxia | 1 | 2019 | 1211 | 0.020 |
Why?
| | Infant | 1 | 2025 | 10114 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 231 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 317 | 0.020 |
Why?
| | Korea | 1 | 2010 | 18 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 47 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 57 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1763 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1077 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2011 | 159 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 183 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4122 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1942 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2010 | 128 | 0.020 |
Why?
| | Pyridoxal Phosphate | 1 | 2009 | 20 | 0.020 |
Why?
| | Edetic Acid | 1 | 2009 | 47 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2001 | 2219 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2010 | 166 | 0.020 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 380 | 0.020 |
Why?
| | Blood Glucose | 3 | 2004 | 2360 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 419 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2008 | 18 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 441 | 0.020 |
Why?
| | Thiazoles | 1 | 2008 | 139 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 545 | 0.020 |
Why?
| | Glyburide | 1 | 2007 | 30 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2007 | 53 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 1133 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 2010 | 307 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2007 | 384 | 0.010 |
Why?
| | Deoxycytidine Kinase | 1 | 2006 | 3 | 0.010 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 712 | 0.010 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2006 | 6 | 0.010 |
Why?
| | Tyrosine | 1 | 2007 | 217 | 0.010 |
Why?
| | Choledochostomy | 1 | 2006 | 9 | 0.010 |
Why?
| | Motorcycles | 1 | 2006 | 7 | 0.010 |
Why?
| | Budd-Chiari Syndrome | 1 | 2006 | 5 | 0.010 |
Why?
| | Mutation | 1 | 2017 | 4093 | 0.010 |
Why?
| | 5'-Nucleotidase | 1 | 2006 | 49 | 0.010 |
Why?
| | Cytidine Deaminase | 1 | 2006 | 59 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 972 | 0.010 |
Why?
| | Phosphorylation | 1 | 2010 | 1724 | 0.010 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 2005 | 55 | 0.010 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 197 | 0.010 |
Why?
| | Methylprednisolone | 1 | 2005 | 58 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 302 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 2005 | 21 | 0.010 |
Why?
| | Maximum Tolerated Dose | 1 | 2005 | 217 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 874 | 0.010 |
Why?
| | Isoantibodies | 1 | 2005 | 58 | 0.010 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 2004 | 5 | 0.010 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2004 | 10 | 0.010 |
Why?
| | Accidents, Traffic | 1 | 2006 | 193 | 0.010 |
Why?
| | DNA Primers | 1 | 2005 | 487 | 0.010 |
Why?
| | Proteomics | 1 | 2011 | 1203 | 0.010 |
Why?
| | Hemorrhage | 1 | 2010 | 825 | 0.010 |
Why?
| | Glucokinase | 1 | 2004 | 15 | 0.010 |
Why?
| | Pyruvate Kinase | 1 | 2004 | 29 | 0.010 |
Why?
| | Intraocular Pressure | 1 | 2006 | 344 | 0.010 |
Why?
| | Tissue Culture Techniques | 1 | 2004 | 82 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2006 | 369 | 0.010 |
Why?
| | Pharmacogenetics | 1 | 2005 | 176 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 2005 | 101 | 0.010 |
Why?
| | Renal Circulation | 1 | 2004 | 75 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 315 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 279 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2003 | 156 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 70 | 0.010 |
Why?
| | Visual Acuity | 1 | 2006 | 499 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 300 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1041 | 0.010 |
Why?
| | Respiratory Insufficiency | 1 | 2006 | 330 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2123 | 0.010 |
Why?
| | Vulvar Diseases | 1 | 2001 | 9 | 0.010 |
Why?
| | Thrombosis | 1 | 2005 | 398 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2001 | 197 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2005 | 287 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1463 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2005 | 536 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 421 | 0.010 |
Why?
| | Morphogenesis | 1 | 2001 | 163 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1114 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2001 | 444 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1765 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2005 | 2012 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2458 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1412 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2001 | 6460 | 0.000 |
Why?
|
|
Del Chiaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|